Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

CRANBURY, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive results from its recently completed Phase 2 clinical trials of Amigal(TM) (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases. The results will be discussed as a part of an "R&D Day" meeting being hosted by the company today from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. A live audio web cast of the presentation will be available to all interested parties through the Company's website at http://www.amicustherapeutics.com. Interested parties should connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An archive of the webcast will be available at the same address until approximately January 2, 2008.

"The completion of these trials is a major milestone for Amicus and these clinical results represent an important proof of concept for the pharmacological chaperone platform technology," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to advancing our program in Fabry as well as Gaucher, Pompe, and other important therapeutic targets utilizing this new approach to the treatment of a wide range of human genetic diseases."

Summary of Study Results:

The primary objective of the Phase 2 trials was to evalu
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... SIRO Clinpharm, an award-winning Clinical ... prestigious Annual Conference of the Society for Clinical Data ... , where they were invited to speak at three ... analytics to support fraud detection, ,clinical data management,s role ... working together as virtual and integrated teams,. The award-winning ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Weighing ... quality of the final product. However, while the ... regulatory frameworks such as Good Manufacturing Practices (GMP) ... responsibility of the manufacturer to interpret these guidelines ... weighing performance quality. METTLER TOLEDO experts have created ...
(Date:10/1/2014)... 2014 Today the National Institutes ... grants for the Brain Research through Advancing Innovative ... develop and revolutionize new methods of understanding the ... brain. This first round of grants totaling $46 ... allocated to more than 100 investigators in 15 ...
(Date:10/1/2014)... TeselaGen Biotechnology has received a ... their bioCAD/CAM software suite, which uses synthetic biology ... Business Innovation Research Phase II grant will be used ... from the Lawrence Berkeley National Laboratory. j5 was developed ... laboratory that develops alternative fuel technologies for the Department ...
Breaking Biology Technology:SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... , SOUTH SAN FRANCISCO, Calif., Sept. ... announced the pricing of an underwritten public offering of 13,000,000 shares ... $7.25 per share. All of the shares are being offered by ... additional 1,950,000 shares to cover over-allotments, if any. The offering is ...
... , , ... ITMN ) today announced that it will be collaborating ... the research of inherited genetic factors that may play a role ... National Jewish with access to DNA collected from patients who participated ...
... , EXTON, Pa., Sept. 16 Kensey Nash ... the 2009 UBS Global Life Sciences conference at the Grand Hyatt ... , , Joseph W. Kaufmann, Kensey Nash,s President ... p.m. (ET). To hear the live webcast of the Kensey ...
Cached Biology Technology:Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
(Date:9/30/2014)... and strawberries all have in common? Unlike most ... and are diploid, these organisms are all polyploid, meaning ... and salmon have 3 and 4 sets of chromosomes, ... seem surprising, in fact most plant species are polyploid. ... century ago, but only recently, with the development of ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Contaminated water linked to pregnancy complications, BU study finds 2
... European researchers have published a study which analyses the health ... of osteoporotic fractures in the population aged over 50. ... that links nutrition and fracture risk, and health economics. It ... countries which have varying levels of dairy product intake in ...
... dynamic role cilia play in guiding the migration of ... structures on the surfaces of cells, but here they ... mouse embryos, researchers were able to see cilia extending ... be receiving signals needed for neurons to find their ...
... for a boat ride or even taken a drink from the ... how valuable? That,s always been a tough question for policy makers ... societal needs that compromise it, such as the need to grow ... so has been greatly enhanced by a new policy-making framework developed ...
Cached Biology News:New health-economic model shows benefits of boosting dietary calcium intake 2Cilia guide neuronal migration in developing brain 2Study offers new tool for incorporating water impacts into policy decisions 2
Lysozyme C (W-20)...
Request Info...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
Biology Products: